secwatch.observer — SEC 8-K summary
======================================

Issuer:     Xeris Biopharma Holdings, Inc. (XERS)
CIK:        0001867096
Form:       8-K
Filed at:   2025-08-07T23:59:59+00:00
Accession:  0001867096-25-000130
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Xeris Biopharma Q2 revenue up 49% to $71.5M; Recorlev +136%; raises FY guidance to $280-290M
--------------------------------------------------------------------------------

- Total revenue $71.5M (+49% YoY); net loss narrowed to $1.9M ($0.01/sh) from $15M ($0.10/sh).
- Recorlev net revenue $31.4M (+136%) driven by 122% increase in average patients on therapy.
- Gvoke revenue $23.5M (+17%); Keveyis $11.5M (-13%) on reduced shipments.
- Adjusted EBITDA improved to $12.5M vs -$0.4M in Q2 2024.
- Raised FY 2025 revenue guidance to $280-290M from $260-275M; long-term target $750M by 2030.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1867096/000186709625000130/0001867096-25-000130-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1867096/000186709625000130/xers-20250807.htm
  HTML page:      https://secwatch.observer/filing/0001867096-25-000130

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer